{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:22:25Z","timestamp":1786972945024,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Differ"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1038\/s41418-023-01232-y","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T13:03:00Z","timestamp":1697461380000},"page":"2447-2451","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["The BCL2 inhibitor venetoclax mediates anticancer effects through dendritic cell activation"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1682-9222","authenticated-orcid":false,"given":"Peng","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1596-0998","authenticated-orcid":false,"given":"Laurence","family":"Zitvogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6081-9558","authenticated-orcid":false,"given":"Oliver","family":"Kepp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9334-4405","authenticated-orcid":false,"given":"Guido","family":"Kroemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,16]]},"reference":[{"key":"1232_CR1","doi-asserted-by":"crossref","first-page":"7166","DOI":"10.1073\/pnas.81.22.7166","volume":"81","author":"L Pegoraro","year":"1984","unstructured":"Pegoraro L, Palumbo A, Erikson J, Falda M, Giovanazzo B, Emanuel BS, et al. A 14;18 and an 8;14 chromosome translocation in a cell line derived from an acute B-cell leukemia. Proc Natl Acad Sci USA 1984;81:7166\u201370.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1232_CR2","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1126\/science.3495884","volume":"236","author":"JC Reed","year":"1987","unstructured":"Reed JC, Tsujimoto Y, Alpers JD, Croce CM, Nowell PC. Regulation of bcl-2 proto-oncogene expression during normal human lymphocyte proliferation. Science. 1987;236:1295\u20139.","journal-title":"Science"},{"key":"1232_CR3","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1073\/pnas.83.14.5214","volume":"83","author":"Y Tsujimoto","year":"1986","unstructured":"Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 1986;83:5214\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1232_CR4","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1084\/jem.184.4.1331","volume":"184","author":"SA Susin","year":"1996","unstructured":"Susin SA, Zamzami N, Castedo M, Hirsch T, Marchetti P, Macho A, et al. Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. J Exp Med. 1996;184:1331\u201341.","journal-title":"J Exp Med"},{"key":"1232_CR5","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1126\/science.275.5303.1129","volume":"275","author":"J Yang","year":"1997","unstructured":"Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science. 1997;275:1129\u201332.","journal-title":"Science"},{"key":"1232_CR6","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1126\/science.275.5303.1132","volume":"275","author":"RM Kluck","year":"1997","unstructured":"Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science. 1997;275:1132\u20136.","journal-title":"Science"},{"key":"1232_CR7","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev.immunol.16.1.395","volume":"16","author":"DT Chao","year":"1998","unstructured":"Chao DT, Korsmeyer SJ. BCL-2 family: regulators of cell death. Annu Rev Immunol. 1998;16:395\u2013419.","journal-title":"Annu Rev Immunol"},{"key":"1232_CR8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1146\/annurev.immunol.21.120601.141029","volume":"21","author":"VS Marsden","year":"2003","unstructured":"Marsden VS, Strasser A. Control of apoptosis in the immune system: Bcl-2, BH3-only proteins and more. Annu Rev Immunol. 2003;21:71\u2013105.","journal-title":"Annu Rev Immunol"},{"key":"1232_CR9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","volume":"20","author":"R Singh","year":"2019","unstructured":"Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol. 2019;20:175\u201393.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1232_CR10","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41580-023-00629-4","volume":"24","author":"PE Czabotar","year":"2023","unstructured":"Czabotar PE, Garcia-Saez AJ. Mechanisms of BCL-2 family proteins in mitochondrial apoptosis. Nat Rev Mol Cell Biol. 2023;24:732\u201348.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1232_CR11","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.cell.2005.07.002","volume":"122","author":"S Pattingre","year":"2005","unstructured":"Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, et al. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell. 2005;122:927\u201339.","journal-title":"Cell"},{"key":"1232_CR12","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/cdd.2017.22","volume":"24","author":"A Gross","year":"2017","unstructured":"Gross A, Katz SG. Non-apoptotic functions of BCL-2 family proteins. Cell Death Differ. 2017;24:1348\u201358.","journal-title":"Cell Death Differ"},{"key":"1232_CR13","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.tcb.2020.03.004","volume":"30","author":"SJF Chong","year":"2020","unstructured":"Chong SJF, Marchi S, Petroni G, Kroemer G, Galluzzi L, Pervaiz S. Noncanonical Cell Fate Regulation by Bcl-2 Proteins. Trends Cell Biol. 2020;30:537\u201355.","journal-title":"Trends Cell Biol"},{"key":"1232_CR14","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","volume":"435","author":"T Oltersdorf","year":"2005","unstructured":"Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435:677\u201381.","journal-title":"Nature"},{"key":"1232_CR15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41568-021-00407-4","volume":"22","author":"ST Diepstraten","year":"2022","unstructured":"Diepstraten ST, Anderson MA, Czabotar PE, Lessene G, Strasser A, Kelly GL. The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. Nat Rev Cancer. 2022;22:45\u201364.","journal-title":"Nat Rev Cancer"},{"key":"1232_CR16","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N. Engl J Med. 2016;374:311\u201322.","journal-title":"N. Engl J Med"},{"key":"1232_CR17","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","volume":"17","author":"S Stilgenbauer","year":"2016","unstructured":"Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17:768\u201378.","journal-title":"Lancet Oncol"},{"key":"1232_CR18","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s40265-016-0596-x","volume":"76","author":"ED Deeks","year":"2016","unstructured":"Deeks ED. Venetoclax: first global approval. Drugs. 2016;76:979\u201387.","journal-title":"Drugs"},{"key":"1232_CR19","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","volume":"19","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19:216\u201328.","journal-title":"Lancet Oncol"},{"key":"1232_CR20","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","volume":"388","author":"B Eichhorst","year":"2023","unstructured":"Eichhorst B, Niemann CU, Kater AP, Furstenau M, von Tresckow J, Zhang C, et al. First-line venetoclax combinations in chronic lymphocytic leukemia. N. Engl J Med. 2023;388:1739\u201354.","journal-title":"N. Engl J Med"},{"key":"1232_CR21","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N. Engl J Med. 2020;383:617\u201329.","journal-title":"N. Engl J Med"},{"key":"1232_CR22","doi-asserted-by":"crossref","unstructured":"Zhao L, Liu P, Mao M, Zhang S, Bigenwald C, Dutertre CA, et al. BCL2 inhibition reveals a dendritic cell-specific immune checkpoint that controls tumor immunosurveillance. Cancer Discov. 2023 Aug 25:CD-22-1338. (Epub ahead of print).","DOI":"10.1158\/2159-8290.24474302.v1"},{"key":"1232_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-immunol-100311-102839","volume":"30","author":"RM Steinman","year":"2012","unstructured":"Steinman RM. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol. 2012;30:1\u201322.","journal-title":"Annu Rev Immunol"},{"key":"1232_CR24","doi-asserted-by":"crossref","first-page":"e62621","DOI":"10.1371\/journal.pone.0062621","volume":"8","author":"C Richter","year":"2013","unstructured":"Richter C, Thieme S, Bandola J, Laugsch M, Anastassiadis K, Brenner S. Generation of inducible immortalized dendritic cells with proper immune function in vitro and in vivo. PLoS One. 2013;8:e62621.","journal-title":"PLoS One"},{"key":"1232_CR25","doi-asserted-by":"crossref","first-page":"100732","DOI":"10.1016\/j.xpro.2021.100732","volume":"2","author":"L Zhao","year":"2021","unstructured":"Zhao L, Liu P, Xie W, Zhang S, Thieme S, Zitvogel L, et al. A genotype-phenotype screening system using conditionally immortalized immature dendritic cells. STAR Protoc. 2021;2:100732.","journal-title":"STAR Protoc"},{"key":"1232_CR26","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2159-8290.CD-20-0465","volume":"11","author":"J Le Naour","year":"2021","unstructured":"Le Naour J, Liu P, Zhao L, Adjemian S, Sztupinszki Z, Taieb J, et al. A TLR3 ligand reestablishes chemotherapeutic responses in the context of FPR1 deficiency. Cancer Discov. 2021;11:408\u201323.","journal-title":"Cancer Discov"},{"key":"1232_CR27","doi-asserted-by":"crossref","first-page":"e006785","DOI":"10.1136\/jitc-2023-006785","volume":"11","author":"S Zhang","year":"2023","unstructured":"Zhang S, Zhao L, Guo M, Liu P, Li S, Xie W, et al. Anticancer effects of ikarugamycin and astemizole identified in a screen for stimulators of cellular immune responses. J Immunother Cancer. 2023;11:e006785.","journal-title":"J Immunother Cancer"},{"key":"1232_CR28","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1073\/pnas.0712394105","volume":"105","author":"ML Lin","year":"2008","unstructured":"Lin ML, Zhan Y, Proietto AI, Prato S, Wu L, Heath WR, et al. Selective suicide of cross-presenting CD8+ dendritic cells by cytochrome c injection shows functional heterogeneity within this subset. Proc Natl Acad Sci USA 2008;105:3029\u201334.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1232_CR29","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nature06175","volume":"449","author":"RM Steinman","year":"2007","unstructured":"Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. 2007;449:419\u201326.","journal-title":"Nature"},{"key":"1232_CR30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1146\/annurev-immunol-061020-053707","volume":"39","author":"M Cabeza-Cabrerizo","year":"2021","unstructured":"Cabeza-Cabrerizo M, Cardoso A, Minutti CM, Pereira da Costa M, Reis e Sousa C. Dendritic cells revisited. Annu Rev Immunol. 2021;39:131\u201366.","journal-title":"Annu Rev Immunol"},{"key":"1232_CR31","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/2159-8290.CD-19-0759","volume":"11","author":"FJ Kohlhapp","year":"2021","unstructured":"Kohlhapp FJ, Haribhai D, Mathew R, Duggan R, Ellis PA, Wang R, et al. Venetoclax increases intratumoral effector T cells and antitumor efficacy in combination with immune checkpoint blockade. Cancer Discov. 2021;11:68\u201379.","journal-title":"Cancer Discov"},{"key":"1232_CR32","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.1164206","volume":"322","author":"K Hildner","year":"2008","unstructured":"Hildner K, Edelson BT, Purtha WE, Diamond M, Matsushita H, Kohyama M, et al. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science. 2008;322:1097\u20131100.","journal-title":"Science"},{"key":"1232_CR33","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.immuni.2013.03.003","volume":"38","author":"Y Ma","year":"2013","unstructured":"Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity. 2013;38:729\u201341.","journal-title":"Immunity"},{"key":"1232_CR34","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","volume":"28","author":"L Galluzzi","year":"2015","unstructured":"Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015;28:690\u2013714.","journal-title":"Cancer Cell"},{"key":"1232_CR35","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ccell.2020.11.009","volume":"39","author":"G Petroni","year":"2021","unstructured":"Petroni G, Buque A, Zitvogel L, Kroemer G, Galluzzi L. Immunomodulation by targeted anticancer agents. Cancer Cell. 2021;39:310\u201345.","journal-title":"Cancer Cell"},{"key":"1232_CR36","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1172\/JCI35180","volume":"118","author":"L Zitvogel","year":"2008","unstructured":"Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, Kroemer G. The anticancer immune response: indispensable for therapeutic success? J Clin Invest. 2008;118:1991\u20132001.","journal-title":"J Clin Invest"},{"key":"1232_CR37","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","volume":"17","author":"L Galluzzi","year":"2020","unstructured":"Galluzzi L, Humeau J, Buque A, Zitvogel L, Kroemer G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020;17:725\u201341.","journal-title":"Nat Rev Clin Oncol"},{"key":"1232_CR38","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1182\/blood-2005-10-4073","volume":"108","author":"M Brune","year":"2006","unstructured":"Brune M, Castaigne S, Catalano J, Gehlsen K, Ho AD, Hofmann WK, et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood. 2006;108:88\u201396.","journal-title":"Blood"},{"key":"1232_CR39","first-page":"368ra171","volume":"8","author":"J Rosenblatt","year":"2016","unstructured":"Rosenblatt J, Stone RM, Uhl L, Neuberg D, Joyce R, Levine JD, et al. Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. Sci Transl Med. 2016;8:368ra171.","journal-title":"Sci Transl Med"},{"key":"1232_CR40","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","volume":"9","author":"N Daver","year":"2019","unstructured":"Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, et al. Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study. Cancer Discov. 2019;9:370\u201383.","journal-title":"Cancer Discov"},{"key":"1232_CR41","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2020007732","volume":"137","author":"GL Uy","year":"2021","unstructured":"Uy GL, Aldoss I, Foster MC, Sayre PH, Wieduwilt MJ, Advani AS, et al. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood. 2021;137:751\u201362.","journal-title":"Blood"},{"key":"1232_CR42","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2010.82","volume":"1","author":"M Wemeau","year":"2010","unstructured":"Wemeau M, Kepp O, Tesniere A, Panaretakis T, Flament C, De Botton S, et al. Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia. Cell Death Dis. 2010;1:e104.","journal-title":"Cell Death Dis"},{"key":"1232_CR43","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.3324\/haematol.2019.223933","volume":"105","author":"I Truxova","year":"2020","unstructured":"Truxova I, Kasikova L, Salek C, Hensler M, Lysak D, Holicek P, et al. Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients. Haematologica. 2020;105:1868\u201378.","journal-title":"Haematologica"},{"key":"1232_CR44","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1182\/blood-2017-02-768762","volume":"131","author":"MA Gillissen","year":"2018","unstructured":"Gillissen MA, Kedde M, Jong G, Moiset G, Yasuda E, Levie SE, et al. AML-specific cytotoxic antibodies in patients with durable graft-versus-leukemia responses. Blood. 2018;131:131\u201343.","journal-title":"Blood"},{"key":"1232_CR45","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.cell.2010.02.015","volume":"140","author":"L Zitvogel","year":"2010","unstructured":"Zitvogel L, Kepp O, Kroemer G. Decoding cell death signals in inflammation and immunity. Cell. 2010;140:798\u2013804.","journal-title":"Cell"},{"key":"1232_CR46","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1146\/annurev-cellbio-111315-125315","volume":"33","author":"PM Henson","year":"2017","unstructured":"Henson PM. Cell removal: efferocytosis. Annu Rev Cell Dev Biol. 2017;33:127\u201344.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"1232_CR47","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1146\/annurev-immunol-042617-053010","volume":"36","author":"S Nagata","year":"2018","unstructured":"Nagata S. Apoptosis and clearance of apoptotic cells. Annu Rev Immunol. 2018;36:489\u2013517.","journal-title":"Annu Rev Immunol"},{"key":"1232_CR48","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41580-018-0068-0","volume":"19","author":"L Galluzzi","year":"2018","unstructured":"Galluzzi L, Yamazaki T, Kroemer G. Linking cellular stress responses to systemic homeostasis. Nat Rev Mol Cell Biol. 2018;19:731\u201345.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1232_CR49","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","volume":"23","author":"G Kroemer","year":"2022","unstructured":"Kroemer G, Galassi C, Zitvogel L, Galluzzi L. Immunogenic cell stress and death. Nat Immunol. 2022;23:487\u2013500.","journal-title":"Nat Immunol"},{"key":"1232_CR50","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41573-022-00470-y","volume":"21","author":"P Mehrotra","year":"2022","unstructured":"Mehrotra P, Ravichandran KS. Drugging the efferocytosis process: concepts and opportunities. Nat Rev Drug Discov. 2022;21:601\u201320.","journal-title":"Nat Rev Drug Discov"},{"key":"1232_CR51","doi-asserted-by":"crossref","unstructured":"Liu P, Zhao L, Zitvogel L, Kepp O, Kroemer G. Immunogenic cell death (ICD) enhancers-drugs that enhance the perception of ICD by dendritic cells. Immunol Rev. 2023 Aug 19. (Epub ahead of print).","DOI":"10.1111\/imr.13269"}],"container-title":["Cell Death &amp; Differentiation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41418-023-01232-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-023-01232-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-023-01232-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T16:03:41Z","timestamp":1703088221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41418-023-01232-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,16]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1232"],"URL":"https:\/\/doi.org\/10.1038\/s41418-023-01232-y","relation":{},"ISSN":["1350-9047","1476-5403"],"issn-type":[{"value":"1350-9047","type":"print"},{"value":"1476-5403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,16]]},"assertion":[{"value":"20 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"OK and GK have been holding research contracts with Daiichi Sankyo, Eleor, Kaleido, Lytix Pharma, PharmaMar, Osasuna Therapeutics, Samsara Therapeutics, Sanofi, Tollys, and Vascage. LZ has held research contracts with Glaxo Smyth Kline, Incyte, Lytix, Kaleido, Innovate Pharma, Daiichi Sankyo, Pilege, Merus, Transgene, 9\u2009m, Tusk and Roche, was on the on the Board of Directors of Transgene, is a cofounder of everImmune, and holds patents covering the treatment of cancer and the therapeutic manipulation of the microbiota. GK is on the Board of Directors of the Bristol Myers Squibb Foundation France. GK is a scientific co-founder of everImmune, Osasuna Therapeutics, Samsara Therapeutics and Therafast Bio. OK is a scientific co-founder of Samsara Therapeutics. GK is in the scientific advisory boards of Hevolution, Institut Servier and Longevity Vision Funds. GK is the inventor of patents covering therapeutic targeting of aging, cancer, cystic fibrosis and metabolic disorders. GK\u2019s brother, Romano Kroemer, was an employee of Sanofi and now consults for Boehringer-Ingelheim. The funders had no role in the design of the study; in the writing of the manuscript, or in the decision to publish the results.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}